MaxCyte (United States)

Biotech company in Rockville, United States

MXCT Nasdaq · home listing MXCT London SE ISIN US57777K1060 SEC CIK 1287098 LEI 54930053YHXULRFCU991
Follow MaxCyte (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $6.2M +34.6% vs same quarter last year
Net income −$4.8M +61.6% vs same quarter last year
EPS, diluted −$0.05 +58.3% vs same quarter last year
Operating cash flow −$5.5M +26.2% vs same quarter last year
Revenue by quarter
$6.1M
$5.7M
$5.8M
$4.6M
$4.8M
$4.5M
$4.9M
$6.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20M$40MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$21M−$44.6M
FY24$22.2M−$41.1M
FY23$19.5M−$37.9M
FY22$28.7M−$23.6M
FY21$21.6M−$19.1M
FY20$15.5M−$11.8M
FY19$13.3M−$12.9M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2570.3%−247.6%−213%
FY2468%−230.5%−184.8%
FY2375.7%−247.7%−194.5%
FY2282.3%−95.2%−82%
FY2183.1%−84.3%−88.5%
FY2082.1%−71.6%−76.5%
FY1981.1%−93.7%−97.3%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$36.2M
FY24−$29.3M
FY23−$25.4M
FY22−$33.3M
FY21−$14.5M
FY20−$10.9M
FY19−$10.1M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • MaxCyte (United States)
  • Healthcare median
−300%−200%−100%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearMaxCyte (United States)Healthcare median
FY25−213%−30.6%
FY24−184.8%−47%
FY23−194.5%−58%
FY22−82%−80.4%
FY21−88.5%−71.8%
FY20−76.5%−62.2%
FY19−97.3%−46.2%
FY18-−49.6%